Navigation Links
U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
Date:4/3/2008

DALLAS and REYKJAVIK, Iceland, April 3, 2008 /PRNewswire/ -- U.S. Preventive Medicine(R), (http://www.USPreventiveMedicine.com) the leader in prevention, and deCODE Genetics, the global leader in gene discovery, today announced they have signed a letter of intent to add genetic testing to expand both companies' personalized medicine services in the U.S. and internationally.

"The signing of the letter of intent with deCODE is significant because we will be the first entity in the U.S. and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine including preventive care, wellness and disease management," said Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. "We are very excited because our consumer, employer and physician customers will now be able to take advantage of a wide range of innovative personalized medicine services, including an opt-in genetic testing program for clients of our Centers for Preventive Medicine and members of The Prevention Plan. Our goal is to make the most advanced prevention strategies -- including more precise risk stratification -- available to informed consumers who want to use the best medicine has to offer to enjoy more good years."

Fey said U.S. Preventive Medicine's expansion into personalized medicine is the next step in the company's plan to provide practical solutions at every point in the healthcare continuum both nationally and internationally.

"The relationship with U.S. Preventive Medicine will offer us another platform to provide our genetic testing and personal genetics services through an innovative business model encompassing Centers for Preventive Medicine, as well as its new Prevention Plan health benefits," says Kari Stefansson, M.D., CEO of deCODE. "This partnership gives deCODE access to an even wider distribution channel of consumers, employers and providers to share knowledge, experiences, new technologies and services, while providing the best possible preventive health programs."

According to U.S. Preventive Medicine National Policy Advisor and former Secretary of the U.S. Department of Health & Human Services, Gov. Tommy Thompson, "The addition of deCODE's DNA profiling services as a option for the individuals the company assists is a natural evolution in the direction of the demand for personalized medicine. This is a very important step for U.S. Preventive Medicine in their role as the leader of this crucial area of health care."

About U.S. Preventive Medicine:

U.S. Preventive Medicine(R), a privately owned company, is building the first personalized medicine business in the United States and internationally focused on prevention. They offer employers, government agencies and consumers proprietary products that include The Prevention Plan(TM), a groundbreaking personalized wellness program delivered online to individuals; The Prevention Plan CM(TM), field-based chronic disease management programs customized for employers and government agencies to reduce healthcare costs; and The Centers for Preventive Medicine(R), which offer high-tech diagnostic screenings delivered to consumers in partnership with hospitals, health systems and other providers. For more information, please visit http://www.USPreventiveMedicine.com.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in personal genome analysis, DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics. Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.


'/>"/>
SOURCE U.S. Preventive Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Preventive Medicine National Policy Advisor Gov. Tommy Thompson to Propose Prevention is the Solution at UBS Global Health Services Conference
2. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
3. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
6. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
7. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
8. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
9. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
10. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
11. Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):